FDA’s orphan drug designations increase for myelofibrosis drugs, reveals GlobalData – Pharma News
Concerns have been raised over the suitability of current FDA-approved treatments for myelofibrosis due to the negative associations with anemia. In response, the FDA has significantly increased the number of awarded orphan drug designations (ODDs) for myelofibrosis-indicated drugs in recent years. Since 2014, a total of 11 ODDs have been granted, with eight of them … Read more